229 related articles for article (PubMed ID: 16424173)
1. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis.
Pan J; Burdick MD; Belperio JA; Xue YY; Gerard C; Sharma S; Dubinett SM; Strieter RM
J Immunol; 2006 Feb; 176(3):1456-64. PubMed ID: 16424173
[TBL] [Abstract][Full Text] [Related]
2. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome.
Belperio JA; Keane MP; Burdick MD; Lynch JP; Xue YY; Li K; Ross DJ; Strieter RM
J Immunol; 2002 Jul; 169(2):1037-49. PubMed ID: 12097412
[TBL] [Abstract][Full Text] [Related]
3. Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy.
Reckamp KL; Figlin RA; Moldawer N; Pantuck AJ; Belldegrun AS; Burdick MD; Strieter RM
J Immunother; 2007; 30(4):417-24. PubMed ID: 17457216
[TBL] [Abstract][Full Text] [Related]
4. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor.
Tannenbaum CS; Tubbs R; Armstrong D; Finke JH; Bukowski RM; Hamilton TA
J Immunol; 1998 Jul; 161(2):927-32. PubMed ID: 9670971
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma.
Suyama T; Furuya M; Nishiyama M; Kasuya Y; Kimura S; Ichikawa T; Ueda T; Nikaido T; Ito H; Ishikura H
Cancer; 2005 Jan; 103(2):258-67. PubMed ID: 15578685
[TBL] [Abstract][Full Text] [Related]
6. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.
Hensbergen PJ; Wijnands PG; Schreurs MW; Scheper RJ; Willemze R; Tensen CP
J Immunother; 2005; 28(4):343-51. PubMed ID: 16000952
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M
J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110
[TBL] [Abstract][Full Text] [Related]
8. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response.
Kondo T; Nakazawa H; Ito F; Hashimoto Y; Osaka Y; Futatsuyama K; Toma H; Tanabe K
Cancer Sci; 2006 Aug; 97(8):780-6. PubMed ID: 16863511
[TBL] [Abstract][Full Text] [Related]
9. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection.
Belperio JA; Keane MP; Burdick MD; Lynch JP; Zisman DA; Xue YY; Li K; Ardehali A; Ross DJ; Strieter RM
J Immunol; 2003 Nov; 171(9):4844-52. PubMed ID: 14568964
[TBL] [Abstract][Full Text] [Related]
10. IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines.
Albanesi C; Scarponi C; Sebastiani S; Cavani A; Federici M; De Pità O; Puddu P; Girolomoni G
J Immunol; 2000 Aug; 165(3):1395-402. PubMed ID: 10903743
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.
Heise CE; Pahuja A; Hudson SC; Mistry MS; Putnam AL; Gross MM; Gottlieb PA; Wade WS; Kiankarimi M; Schwarz D; Crowe P; Zlotnik A; Alleva DG
J Pharmacol Exp Ther; 2005 Jun; 313(3):1263-71. PubMed ID: 15761110
[TBL] [Abstract][Full Text] [Related]
12. The Role of Chemokine Receptor CXCR3 and Its Ligands in Renal Cell Carcinoma.
Gudowska-Sawczuk M; Kudelski J; Mroczko B
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202536
[TBL] [Abstract][Full Text] [Related]
13. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11.
Xanthou G; Duchesnes CE; Williams TJ; Pease JE
Eur J Immunol; 2003 Aug; 33(8):2241-50. PubMed ID: 12884299
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation.
Xanthou G; Williams TJ; Pease JE
Eur J Immunol; 2003 Oct; 33(10):2927-36. PubMed ID: 14515277
[TBL] [Abstract][Full Text] [Related]
15. CXCL10 is the key ligand for CXCR3 on CD8+ effector T cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system.
Christensen JE; de Lemos C; Moos T; Christensen JP; Thomsen AR
J Immunol; 2006 Apr; 176(7):4235-43. PubMed ID: 16547260
[TBL] [Abstract][Full Text] [Related]
16. TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis.
Loos T; Dekeyzer L; Struyf S; Schutyser E; Gijsbers K; Gouwy M; Fraeyman A; Put W; Ronsse I; Grillet B; Opdenakker G; Van Damme J; Proost P
Lab Invest; 2006 Sep; 86(9):902-16. PubMed ID: 16847431
[TBL] [Abstract][Full Text] [Related]
17. Elevated expression of IFN-inducible CXCR3 ligands predicts poor prognosis in patients with non-metastatic clear-cell renal cell carcinoma.
Liu W; Liu Y; Fu Q; Zhou L; Chang Y; Xu L; Zhang W; Xu J
Oncotarget; 2016 Mar; 7(12):13976-83. PubMed ID: 26910919
[TBL] [Abstract][Full Text] [Related]
18. CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11).
Sauty A; Colvin RA; Wagner L; Rochat S; Spertini F; Luster AD
J Immunol; 2001 Dec; 167(12):7084-93. PubMed ID: 11739530
[TBL] [Abstract][Full Text] [Related]
19. The production of CXCR3-agonistic chemokines by synovial fibroblasts from patients with rheumatoid arthritis.
Ueno A; Yamamura M; Iwahashi M; Okamoto A; Aita T; Ogawa N; Makino H
Rheumatol Int; 2005 Jun; 25(5):361-7. PubMed ID: 15004722
[TBL] [Abstract][Full Text] [Related]
20. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids.
Proost P; Verpoest S; Van de Borne K; Schutyser E; Struyf S; Put W; Ronsse I; Grillet B; Opdenakker G; Van Damme J
J Leukoc Biol; 2004 May; 75(5):777-84. PubMed ID: 14996826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
